Learning from the past for TB drug discovery in the future

Drug Discov Today. 2017 Mar;22(3):534-545. doi: 10.1016/j.drudis.2016.09.025. Epub 2016 Oct 4.


Tuberculosis drug discovery has shifted in recent years from a primarily target-based approach to one that uses phenotypic high-throughput screens. As examples of this, through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project predominantly used phenotypic screening. From these projects we have examples of success (DprE1) and failure (PimA) going from drug to target and from target to drug, respectively. It is clear that we still have much to learn about the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis. We propose a more integrated approach that learns from earlier drug discovery efforts that could help to move drug discovery forward.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alcohol Oxidoreductases / metabolism
  • Animals
  • Antitubercular Agents*
  • Bacterial Proteins / metabolism
  • Drug Discovery*
  • Humans
  • Machine Learning
  • Mannosyltransferases / metabolism
  • Tuberculosis / drug therapy


  • Antitubercular Agents
  • Bacterial Proteins
  • Alcohol Oxidoreductases
  • DprE1 protein, Mycobacterium tuberculosis
  • Mannosyltransferases